HCA Healthcare, Inc. (HCA) will report second quarter 2026 earnings on April 24 after market close. Analysts expect earnings per share of $7.16 and revenue of $19.08 billion. The healthcare giant operates 182 hospitals and numerous outpatient facilities across 20 states and England. With a market cap of $105.4 billion and stock price at $471.34, HCA remains a major player in the medical care facilities sector. Meyka AI rates HCA with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors. Investors should watch how the company navigates ongoing healthcare demand and operational efficiency.
Earnings Estimates and Historical Performance
Analysts project HCA will deliver $7.16 in earnings per share for the upcoming quarter. Revenue expectations stand at $19.08 billion. These estimates reflect steady growth expectations in the healthcare sector.
Recent Earnings Track Record
HCA has demonstrated consistent earnings growth over the past four quarters. In January 2026, the company beat EPS estimates by delivering $8.01 versus the $7.46 estimate. Revenue came in at $19.51 billion against a $19.68 billion estimate. The July 2025 quarter showed $6.84 EPS versus $6.29 expected, and $18.61 billion in revenue versus $18.50 billion estimated. This pattern reveals HCA regularly exceeds EPS expectations while occasionally missing revenue targets slightly.
What the Numbers Mean
The current $7.16 EPS estimate represents a 10.8% increase from the July 2025 quarter’s $6.84 actual result. Revenue guidance of $19.08 billion sits between recent quarterly performance levels. The company’s consistent ability to beat EPS estimates suggests strong operational execution and cost management. However, revenue estimates remain modest, indicating cautious analyst sentiment about patient volume growth.
Key Metrics and Financial Health
HCA’s financial position shows mixed signals worth monitoring. The company trades at a PE ratio of 16.63, slightly below the S&P 500 average. Operating margins stand at 15.8%, reflecting solid profitability in healthcare operations.
Cash Flow and Liquidity
Operating cash flow per share reached $54.77 trailing twelve months, while free cash flow per share stands at $33.34. These metrics demonstrate HCA’s ability to generate cash from core operations. The company maintains a current ratio of 0.83, which is tight but typical for healthcare operators managing large patient receivables. Interest coverage of 5.32x provides adequate cushion for debt service obligations.
Debt and Capital Structure
HCA carries significant debt with a debt-to-assets ratio of 0.83. Net debt to EBITDA stands at 3.15x, indicating moderate leverage. The company’s capital structure reflects typical healthcare industry practices, where debt financing supports facility expansion and equipment purchases. Investors should monitor whether management maintains disciplined capital allocation during the earnings call.
What to Watch During the Earnings Report
Several factors will shape investor reaction to HCA’s Q2 2026 results. Management commentary on patient volumes, pricing power, and labor costs will prove critical. Healthcare operators face ongoing wage pressure and staffing challenges that directly impact margins.
Operational Metrics
Investors should focus on same-hospital revenue growth, which isolates organic performance from acquisitions. Admission rates and average length of stay indicate patient demand trends. Operating margin expansion or contraction signals management’s success controlling costs. The company’s guidance for the remainder of 2026 will heavily influence stock movement following the announcement.
Guidance and Forward Outlook
Management’s commentary on Medicare reimbursement rates, commercial insurance negotiations, and elective procedure demand matters significantly. Any changes to full-year earnings guidance could trigger substantial stock volatility. Analysts will also probe capital allocation plans, including share buybacks and dividend policy. The company’s ability to maintain pricing power amid competitive pressures will shape long-term investor confidence.
Analyst Consensus and Stock Outlook
Wall Street maintains a predominantly bullish stance on HCA. Twenty-four analysts rate the stock as a buy, while six recommend hold and one suggests sell. This 24-to-1 buy-to-sell ratio reflects broad confidence in the healthcare operator’s business model and growth prospects.
Price Targets and Valuation
The stock trades near its 50-day moving average of $509.78, suggesting recent consolidation. Year-to-date performance shows modest gains of 0.98%, while the one-year return reaches 45.2%. The 52-week range spans $321.39 to $556.52, with the current price near the midpoint. Meyka AI rates HCA with a grade of B+, indicating solid fundamental strength relative to sector peers and broader market benchmarks.
Beat or Miss Prediction
Based on HCA’s consistent pattern of beating EPS estimates while occasionally missing revenue targets, the company appears positioned to exceed the $7.16 EPS estimate. Historical data shows the company beat EPS in three of the last four quarters. Revenue could come in slightly below the $19.08 billion estimate, following recent trends. Investors should expect a positive earnings surprise on the bottom line.
Final Thoughts
HCA Healthcare enters Q2 2026 earnings with strong momentum and 24 buy ratings. The company consistently beats EPS estimates with solid operational metrics and a B+ grade, indicating strong management execution. Key focus areas include patient volume trends, margin sustainability, and full-year guidance. With the stock near historical midpoints, HCA appears fairly valued for healthcare investors seeking hospital and outpatient exposure. The April 24 earnings announcement should reinforce positive consensus unless management signals unexpected reimbursement or labor cost pressures.
FAQs
What EPS and revenue are analysts expecting for HCA’s Q2 2026 earnings?
Analysts expect HCA to report earnings per share of $7.16 and revenue of $19.08 billion for Q2 2026. These estimates reflect steady growth from recent quarters and analyst confidence in the company’s operational performance.
Has HCA beaten earnings estimates in recent quarters?
Yes, HCA has a strong track record of beating EPS estimates. In the last four quarters, the company exceeded EPS expectations in three instances, including delivering $8.01 versus $7.46 expected in January 2026.
What is Meyka AI’s grade for HCA Healthcare?
Meyka AI rates HCA with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.
What should investors watch during HCA’s earnings call?
Investors should monitor same-hospital revenue growth, patient admission trends, operating margin changes, and management guidance for 2026. Commentary on labor costs, Medicare reimbursement, and capital allocation plans will significantly impact stock movement.
What is the analyst consensus rating for HCA stock?
Wall Street is bullish on HCA with 24 buy ratings, 6 hold ratings, and 1 sell rating. This strong buy-to-sell ratio reflects broad confidence in the healthcare operator’s business model and growth prospects.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)